Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kovar

Showing results (861-870 of 949) with videos related to

Pageof 95
Sort By:
Cell Death & Disease|July 25, 2018
Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformationTahereh Javaheri, Zahra Kazemi, Jan Pencik, et al.
Cell Death & Disease|August 14, 2019
Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformationTahereh Javaheri, Zahra Kazemi, Jan Pencik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian CancerTereza Lanickova, Michal Hensler, Lenka Kasikova, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agentQun Li, Keith W Woods, Akiyo Claiborne, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinasesSteve D Fidanze, Scott A Erickson, Gary T Wang, et al.
Journal of Medicinal Chemistry|September 10, 1999
Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacyS J O'Connor, K J Barr, L Wang, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|February 23, 2010
International exercise on 124Sb photon emission intensities determinationM-M Bé, B Chauvenet, M-N Amiot, et al.
Neurology|September 29, 2020
Thrombectomy vs medical management in low NIHSS acute anterior circulation strokeOndrej Volny, Charlotte Zerna, Ales Tomek, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Pageof 95

Showing results (861-870 of 949) with videos related to

Sort By:
Pageof 95
Cell Death & Disease|July 25, 2018
Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformationTahereh Javaheri, Zahra Kazemi, Jan Pencik, et al.
Cell Death & Disease|August 14, 2019
Retraction Note: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformationTahereh Javaheri, Zahra Kazemi, Jan Pencik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian CancerTereza Lanickova, Michal Hensler, Lenka Kasikova, et al.
Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agentQun Li, Keith W Woods, Akiyo Claiborne, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinasesSteve D Fidanze, Scott A Erickson, Gary T Wang, et al.
Journal of Medicinal Chemistry|September 10, 1999
Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacyS J O'Connor, K J Barr, L Wang, et al.
BMC Cancer|December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerHelmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|February 23, 2010
International exercise on 124Sb photon emission intensities determinationM-M Bé, B Chauvenet, M-N Amiot, et al.
Neurology|September 29, 2020
Thrombectomy vs medical management in low NIHSS acute anterior circulation strokeOndrej Volny, Charlotte Zerna, Ales Tomek, et al.
Journal of Medicinal Chemistry|April 24, 2020
Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second BromodomainGeorge S Sheppard, Le Wang, Steven D Fidanze, et al.
Pageof 95